Cue Health shares rose 12% Tuesday to close at 59 cents. Cue Health s Covid-19 Test Gets FDA Marketing Authorization, at 4:16 p.m. ET, incorrectly said the rise was in after-hours trading. . | June 6, 2023
The U.S. Food and Drug Administration
on Tuesday approved Cue Health s at-home COVID-19 test,
the first coronavirus test to get marketing authorization using
a traditional premarket review, the agency. | June 6, 2023
Cue’s COVID-19 Molecular Test detects all known variants of concern and seamlessly integrates with Cue Care, the company’s innovative test-to-treatment platform
. | June 6, 2023
Cue Health Achieves Groundbreaking Milestone with FDA: First Company to Receive De Novo Authorization for a COVID-19 Home Use Test Cue s COVID-19 Molecular Test. | June 6, 2023
By Sabela Ojea Cue Health said Tuesday that its Covid-19 molecular test has received a De Novo marketing authorization from the U.S. Food and Drug Administration. Shares climbed 12% to 59. | June 6, 2023